Technology | Analytics Software | May 16, 2019

Biosense Webster Launches Cartonet Analytics Software for Electrophysiology

Software provides cloud-based network for electrophysiologists to review, analyze and share atrial fibrillation case data to improve procedural efficiency

Biosense Webster Launches Cartonet Analytics Software for Electrophysiology

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced the launch of Biosense Webster Inc.’s Cartonet to help electrophysiologists, hospitals, health systems, and researchers leverage and share data, with the goal of improving patient outcomes and operational efficiency in catheter ablation procedures. Announced at Heart Rhythm 2019, the Heart Rhythm Society's (HRS) 40th Annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco, Cartonet is the world’s first cloud-based networking and data analytics software solution for the field of electrophysiology, according to the company.

Cartonet gives doctors and hospitals the ability to review, analyze and share case data, along with video and image files obtained during catheter ablation procedures with Biosense Webster’s Carto 3 three-dimensional heart mapping system. With Cartonet, Carto 3 systems data will be stored on a secure cloud-based network where doctors can remotely access it via laptop, tablet or desktop. An interactive clinical dashboard provides statistics and analytics on case volume, lab utilization and procedural efficiency, among other data points. In addition, case data may be shared between institutions for clinical and research purposes.

Cartonet leverages the teamplay Cloud Platform of Siemens Healthineers, one of the largest data networks in healthcare with more than 3,600 connected institutions in 59 countries. The teamplay Cloud Platform meets industry best practices of security and privacy and supports compliance with HIPAA and GDPR.

“This is a very exciting development for the field of electrophysiology in that we will be able to more powerfully harness catheter ablation data to hone our own processes in the lab and to generate evidence and collaborate on research that could lead to new advances and improved patient outcomes,” said Jose Osorio, M.D., director, cardiac electrophysiology, Grandview Medical Center, Birmingham, Ala., who used Cartonet in a pilot program prior to its launch.

Catheter ablation is a proven safe and effective non-surgical treatment option for heart rhythm disorders including atrial fibrillation (AF). It works through neutralizing the abnormal electrical activity that causes an irregular heartbeat. Most patients who have the procedure experience a long-term reduction in the number of episodes of arrhythmia and the severity of symptoms. A high percentage achieve a permanent return to normal heart rhythm.

For more information: www.biosensewebster.com

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init